• Eli Lilly (NYSE:LLY) is moving into vaccines and infectious diseases with three acquisitions, reportedly totaling nearly $4 billion for Curevo, LimmaTech Biologics, and Vaccine Company.
• The company is reporting strong Phase 3 results for obesity and diabetes drug candidates Foundayo and retatrutide.
• New data in menopause and broader women’s health is expanding Eli Lilly’s potential treatment areas.

Eli Lilly, trading at about $1,149.15, has delivered gains of about 432.8% over the past five years and 163.6% over the past three years. Over the past year, the stock is up 49.6%, with shorter-term returns of 21.2% over 30 days and 6.2% over the past week, which reflects recent momentum around its obesity and diabetes portfolio.

The move into vaccines and infectious diseases sits alongside late-stage obesity and diabetes programs and emerging women’s health assets. Together, these areas broaden Eli Lilly’s potential revenue mix. For investors, the combination of new therapeutic areas and established GLP-1 leadership can influence how to think about long-term durability and the range of outcomes that might matter for NYSE:LLY.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$1,149.15, the stock is about 5.4% below the US$1,215 price target, which sits inside a wide US$850 to US$1,500 range.
• ✅ Simply Wall St Valuation: Shares are flagged as trading about 18.2% below an internal fair value estimate, which points to an undervalued status.
• ✅ Recent Momentum: A 21.2% gain over 30 days suggests traders are already reacting to the vaccine acquisitions and late stage obesity and diabetes data.

There's only one way to know the right time to buy, sell or hold Eli Lilly. Head to Simply Wall St's company report for the latest analysis of Eli Lilly's Fair Value.

Key Considerations

• 📊 The push into vaccines, infectious diseases and women’s health adds new product lines that can matter alongside the existing GLP-1 obesity and diabetes franchise.
• 📊 Watch how vaccine and infectious disease assets progress through trials and how Phase 3 obesity and diabetes results translate into revenue and earnings against the current P/E of 40.5.
• ⚠️ The company carries a high level of debt and one risk relates to high non cash earnings, so you should track balance sheet trends and earnings quality alongside growth headlines.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Eli Lilly analysis. Alternatively, you can check out the community page for Eli Lilly to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.